Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy.
Publication
, Journal Article
Feng, KY; Loungani, RS; Rao, VN; Patel, CB; Khouri, MG; Felker, GM; DeVore, AD
Published in: JACC CardioOncol
December 2019
Transthyretin amyloid cardiomyopathy (ATTR-CM) has emerged as an increasingly identified etiology of heart failure. Fortunately, the disease now has an approved therapy, with many others under development. Assessment of prognosis in ATTR-CM is critical to inform patients about the disease course and guide clinical decisions. This review discusses the evidence behind clinical, biomarker, and imaging findings that inform prognosis in patients with ATTR-CM and can assist providers in the shared decision-making process during management of this disease.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
JACC CardioOncol
DOI
EISSN
2666-0873
Publication Date
December 2019
Volume
1
Issue
2
Start / End Page
273 / 279
Location
United States
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3201 Cardiovascular medicine and haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Feng, K. Y., Loungani, R. S., Rao, V. N., Patel, C. B., Khouri, M. G., Felker, G. M., & DeVore, A. D. (2019). Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy. JACC CardioOncol, 1(2), 273–279. https://doi.org/10.1016/j.jaccao.2019.11.006
Feng, Kent Y., Rahul S. Loungani, Vishal N. Rao, Chetan B. Patel, Michel G. Khouri, G Michael Felker, and Adam D. DeVore. “Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy.” JACC CardioOncol 1, no. 2 (December 2019): 273–79. https://doi.org/10.1016/j.jaccao.2019.11.006.
Feng KY, Loungani RS, Rao VN, Patel CB, Khouri MG, Felker GM, et al. Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy. JACC CardioOncol. 2019 Dec;1(2):273–9.
Feng, Kent Y., et al. “Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy.” JACC CardioOncol, vol. 1, no. 2, Dec. 2019, pp. 273–79. Pubmed, doi:10.1016/j.jaccao.2019.11.006.
Feng KY, Loungani RS, Rao VN, Patel CB, Khouri MG, Felker GM, DeVore AD. Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy. JACC CardioOncol. 2019 Dec;1(2):273–279.
Published In
JACC CardioOncol
DOI
EISSN
2666-0873
Publication Date
December 2019
Volume
1
Issue
2
Start / End Page
273 / 279
Location
United States
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3201 Cardiovascular medicine and haematology